Doxorubicin 75mg/M2 followed by cyclophosphamide, methotrexate, and fluorouracil (A=> CMF) in the adjuvant treatment of node positive breast cancer: Outcome and toxicity in 136 patients

Abstract

849 Background: After the 1991 publication from Milan showing the advantage of A=> CMF compared to alternating CMF/A therapy, we elected to treat women with intermediate risk stage II breast cancer, with a similar combination. The objective of the study was to assess the effectiveness and tolerability of a modified A=> CMF regimen. Methods: From August 1991 till January 2003, 136 breast cancer patients, median age 45y (range 24–70) with T 1–2 N>3 (66 pts) or if less (70 pts), have at least two out of the following bad prognostic markers: very young age, negative receptors, grade III and vascular invasion. Grade I, II or III Infiltrating duct was noted in 8, 70 and 33 of the specimens respectively and positive receptors were detected in 78 of the tumors. The modified treatment was Doxorubicin (A) 75mg/M2 Q 21D × 4 followed by Cyclophosphamide 600mg/M2, Methotrexate 40mg/M2 and 5 Fluorouracyl 600mg/M2 day 1,8 Q 28D × 4. 122 patients were treated with local radiotherapy: All pts after conservative surgery an...